8-K: Palatin Technologies Announces Second Quarter Fiscal Year 2024 Results and Provides Corporate Update

Palatin Technologies reported its second quarter fiscal year 2024 financial results, highlighted by the completion of the Vyleesi asset sale and progress in its melanocortin receptor pipeline.

Summary

• Palatin Technologies announced its financial results for the second quarter of fiscal year 2024, ending December 31, 2023.
• The company completed the sale of its Vyleesi asset to Cosette Pharmaceuticals for up to $171 million, including $12 million upfront and up to $159 million in sales-based milestones.
• Palatin received $15 million in gross proceeds from equity offerings.
• Vyleesi gross product sales were $4.3 million, with net product revenue of $2.0 million, compared to $2.6 million and $1.0 million respectively in the same quarter last year.
• Total operating expenses were $0.9 million, which includes a $7.8 million gain on the sale of Vyleesi.
• The company reported a net loss of $7.8 million, or $(0.56) per share, compared to a net income of $2.7 million, or $0.25 per share, for the same period last year.
• Palatin's cash, cash equivalents, and marketable securities were $9.5 million as of December 31, 2023, with an additional $2.3 million in accounts receivable.
• The company expects its current cash position, along with recent proceeds from a registered direct offering, to fund operations into the second half of calendar year 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the sale of Vyleesi and progress in the pipeline are positive, the net loss and increased cash burn are concerning. The company's future success depends on the results of its clinical trials and its ability to secure additional funding.

Positives

• The sale of Vyleesi provides a significant cash infusion and potential future revenue through milestones.
• Net product revenue from Vyleesi increased by 98% year-over-year.
• Operating expenses decreased significantly due to the gain on the sale of Vyleesi.
• The company has secured additional funding through equity offerings.
• Palatin has multiple topline data readouts expected in the near future from its clinical trials.
• The company is initiating two new Phase 2 clinical trials in the first half of calendar year 2024.

Negatives

• The company reported a net loss of $7.8 million for the quarter, compared to a net income of $2.7 million in the same period last year.
• The net loss was primarily due to a change in the fair value of warrant liabilities.
• Cash used in operations increased to $10.5 million from $9.7 million in the same period last year.

Risks

• The company's financial performance is subject to fluctuations in the fair value of warrant liabilities.
• The company's future success depends on the successful development and commercialization of its pipeline products.
• Clinical trial results may not be positive, and regulatory approvals may not be granted.
• The company may need to raise additional capital in the future to fund its operations.

Future Outlook

The company anticipates multiple topline data readouts from its clinical trials in the near future and plans to initiate two new Phase 2 clinical studies in the first half of calendar year 2024. Palatin believes its current cash position will fund operations into the second half of calendar year 2024.

Management Comments

• With the planned divestiture of Vyleesi completed, our focus is solely on advancing our robust melanocortin-based development and clinical pipeline, said Carl Spana, Ph.D., President and CEO of Palatin.
• We have multiple topline data result readouts in the near future, notably our MELODY-1 pivotal Phase 3 dry eye disease trial, our Phase 2 ulcerative colitis trial and our Phase 2 diabetic kidney disease study.
• We are also excited to commence two new clinical trials in the first half of calendar year 2024, with topline data readouts in the second half of calendar year 2024.

Industry Context

Palatin's focus on melanocortin receptor modulation aligns with a growing interest in targeted therapies for inflammatory, metabolic, and sexual health conditions. The sale of Vyleesi allows the company to concentrate on its core pipeline, which includes potential treatments for dry eye disease, ulcerative colitis, diabetic kidney disease, obesity, and erectile dysfunction. This strategy is consistent with other biopharmaceutical companies that focus on specific therapeutic areas.

Comparison to Industry Standards

• Palatin's 98% increase in Vyleesi net product revenue year-over-year is a positive sign, but the overall revenue is still relatively low compared to established pharmaceutical companies.
• The company's operating expenses are low due to the gain on the sale of Vyleesi, but this is not a sustainable trend.
• The net loss of $7.8 million is a concern, especially when compared to the net income of $2.7 million in the same period last year. This is largely due to the change in fair value of warrant liabilities, which is a non-cash item.
• The company's cash position of $9.5 million, plus $2.3 million in accounts receivable, is relatively low for a company with multiple ongoing clinical trials. However, the company has stated that this is sufficient to fund operations into the second half of calendar year 2024.
• Other companies in the biopharmaceutical space with similar pipelines, such as those focused on autoimmune or metabolic diseases, often have higher cash burn rates and may require more frequent capital raises.

Stakeholder Impact

• Shareholders may be concerned about the net loss but encouraged by the progress in the pipeline and the sale of Vyleesi.
• Employees may be affected by the company's strategic shift and focus on the melanocortin receptor pipeline.
• Customers and patients may benefit from the development of new treatments for various conditions.
• Creditors may be interested in the company's cash position and ability to meet its obligations.

Next Steps

• The company expects topline data readouts from the MELODY-1 Phase 3 dry eye disease trial in February.
• An interim analysis of the Phase 2 ulcerative colitis trial is expected in the second quarter of calendar year 2024.
• Topline results from the Phase 2 diabetic kidney disease study are expected in the second quarter of calendar year 2024.
• The company plans to start a Phase 2 clinical study of a MCR4 agonist plus a GLP-1 in obese patients in the first half of calendar year 2024.
• A Phase 2 clinical study evaluating bremelanotide co-formulated with a PDE5i for erectile dysfunction is also expected to commence in the first half of calendar year 2024.
• Initiation of investigational new drug (IND) enabling activities for a novel MCR4 selective long-acting agonist is expected in the second half of calendar 2024.

Key Dates

Keywords

Palatin Technologies, Vyleesi, Melanocortin Receptor, Clinical Trials, Dry Eye Disease, Ulcerative Colitis, Diabetic Kidney Disease, Obesity, Erectile Dysfunction, Financial Results, Biopharmaceutical